Literature DB >> 33588871

Portable continuous wave Doppler ultrasound for primary healthcare in South Africa: can the EUnetHTA Core Model guide evaluation before technology adoption?

Debjani Mueller1,2, Robert C Pattinson3,4,5, Tsakane M Hlongwane3,4,5, Reinhard Busse6, Dimitra Panteli7.   

Abstract

BACKGROUND: This study had a threefold aim: to test the value of stakeholder involvement in HTA to reduce evidence gaps and interpret findings; and to assess a medical device by applying the EUnetHTA Core Model (CM) in South Africa and thus ultimately provide a first overview of evidence for potential widespread adoption of the technology in a primary health care (PHC) setting. Used in primary healthcare setting for obstetric use, the technology under assessment is a low-cost continuous wave Doppler ultrasound (DUS).
METHODS: The scoping of the assessment was defined by involving policy makers in selecting the domains and corresponding questions relevant to the ultrasound and its use. Additionally, hospital managers were invited to respond to dichotomous questions on the criteria for procurement. To substantiate evidence obtained from an initial literature review, different stakeholders were identified and consulted. The evidence generated fromall steps was used to populate the high-ranked assessment elements of the CM.
RESULTS: The HTA on continuous-wave DUS incorporated the evidence on organizational, ethical, and social value of its use together with effectiveness, safety, and cost-effectiveness of the technology. The domains on "health problem" and "safety" had a higher rank than the rest of the nine domains. Unexplained fetal mortality is the largest single contributor to perinatal deaths in South Africa. Pregnant women in PHC setting were examined using a continuous-wave DUS, after their routine antenatal visit. The healthcare professionals interviewed, indicated the benefit in the use of continuous-wave DUS in the PHC setting and the need for training.
CONCLUSIONS: Collection and generation of evidence based on the HTA CM and the chosen decision criteria provided a generalized but structured guidance on the methodology. Several questions were not applicable for the technology and the context of its use and elimination of those that are inappropriate for the African context, resulted in a pragmatic solution. Engaging and consulting local stakeholders was imperative to understand the context, reduce evidence gaps, and address the uncertainties in the evidence, ultimately paving the way for technology adoption. Given the ongoing studies and the evolving evidence base, the potential of this technology should be reassessed.

Entities:  

Keywords:  Doppler ultrasound; Health technology assessment; South africa

Year:  2021        PMID: 33588871      PMCID: PMC7885360          DOI: 10.1186/s12962-021-00261-z

Source DB:  PubMed          Journal:  Cost Eff Resour Alloc        ISSN: 1478-7547


  4 in total

1.  Obstetric ultrasound education for the developing world: A learning partnership with the World Federation for Ultrasound in Medicine and Biology.

Authors:  N Baj; P Dubbins; J A Evans
Journal:  Ultrasound       Date:  2015-01-10

2.  Global, regional, and national levels and trends in under-5 mortality between 1990 and 2015, with scenario-based projections to 2030: a systematic analysis by the UN Inter-agency Group for Child Mortality Estimation.

Authors:  Danzhen You; Lucia Hug; Simon Ejdemyr; Priscila Idele; Daniel Hogan; Colin Mathers; Patrick Gerland; Jin Rou New; Leontine Alkema
Journal:  Lancet       Date:  2015-09-08       Impact factor: 79.321

Review 3.  Urine tests for Down's syndrome screening.

Authors:  S Kate Alldred; Boliang Guo; Yemisi Takwoingi; Mary Pennant; Susanna Wisniewski; Jonathan J Deeks; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2015-12-10

Review 4.  Pharmacological and mechanical interventions for labour induction in outpatient settings.

Authors:  Joshua P Vogel; Alfred O Osoti; Anthony J Kelly; Stefania Livio; Jane E Norman; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2017-09-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.